Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma Presented ByDr Steven Horwitz , Memorial Sloan Kettering Cancer Center, USA TrialPhase 3, ECHELON-1 ConferenceEHA 2019 9 August, 2019 20:49
